Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer's disease.

The emerging evidence from biomarker and clinical studies suggests MBI can be an early manifestation of underlying neurodegenerative disease. Future research must now further validate MBI to improve identification of those at the very earliest stages of disease.